List view / Grid view
7 October 2013 | By Publicis Life Brands Resolute
New report presents unique statistics on health R&D in the European Union...
7 October 2013 | By Nobel Prize
The 2013 Nobel Prize honours three scientists who have solved the mystery of how the cell organizes its transport system...
5 October 2013 | By Novartis
"The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond..."
4 October 2013 | By Teva Pharmaceutical Industries Ltd
Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis...
4 October 2013 | By Novartis
"The data presented today are very encouraging because they are from studies that took place over four years..."
4 October 2013 | By GlaxoSmithKline
GlaxoSmithKline plc and Genmab announced the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra...
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
4 October 2013 | By Biogen Idec
Interim results from ENDORSE extension study reinforce favorable safety profile in patients treated for up to six and a half years...
3 October 2013 | By Sanofi
Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden...
3 October 2013 | By Biogen Idec
“These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease..."
3 October 2013 | By Amgen
"The Phase 2 data demonstrate that the primary and secondary end points were met..."
3 October 2013 | By Pfizer Inc.
“The approval of DUAVEE, an important, novel and effective treatment, presents a new opportunity for women..."
3 October 2013 | By Celgene
Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID...
AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1
3 October 2013 | By Johnson & Johnson
Collaborations announced between regional innovators and Johnson & Johnson family of companies...
